Abstract
Original language | English |
---|---|
Pages (from-to) | 2906-2920 |
Number of pages | 15 |
Journal | Allergy: European Journal of Allergy and Clinical Immunology |
Volume | 78 |
Issue number | 11 |
Early online date | 2023 |
DOIs | |
Publication status | Published - Nov 2023 |
Keywords
- Haemophilus influenzae
- Moraxella catarrhalis
- Tropheryma whipplei
- severe asthma
- α-diversity
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, No. 11, 11.2023, p. 2906-2920.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Haemophilus influenzae and Moraxella catarrhalis in sputum of severe asthma with inflammasome and neutrophil activation
AU - Versi, Ali
AU - Ivan, Fransiskus Xaverius
AU - Abdel-Aziz, Mahmoud I.
AU - Bates, Stewart
AU - Riley, John
AU - Baribaud, Frederic
AU - Kermani, Nazanin Zounemat
AU - Montuschi, Paolo
AU - Dahlen, Sven-Erik
AU - Djukanovic, Ratko
AU - Sterk, Peter
AU - Maitland-van der Zee, Anke H.
AU - Chotirmall, Sanjay H.
AU - Howarth, Peter
AU - Adcock, Ian M.
AU - Chung, Kian Fan
AU - U-BIOPRED Consortium
AU - Andersson, L. I.
AU - Auffray, C.
AU - Badi, Y. E.
AU - Bakke, P.
AU - Bansal, A. T.
AU - Bel, E. H.
AU - Bigler, J.
AU - Billing, B.
AU - Bisgaard, H.
AU - Boedigheimer, M. J.
AU - Bønnelykke, K.
AU - Brandsma, J.
AU - Brinkman, P.
AU - Bucchioni, E.
AU - Burg, D.
AU - Bush, A.
AU - Caruso, M.
AU - Chalekis, R.
AU - Chanez, P.
AU - Checa, T.
AU - Compton, C. H.
AU - Corfield, J.
AU - Cunoosamy, D.
AU - Dahlén, B.
AU - Dahlén, S. E.
AU - de Meulder, B.
AU - Erpenbeck, V. J.
AU - Erzen, D.
AU - Fichtner, K.
AU - Fleming, L. J.
AU - Formaggio, E.
AU - Hashimoto, S.
AU - Hekking, P. W.
AU - Lutter, R.
AU - Fowler, S. J.
N1 - Funding Information: U-BIOPRED has received funding from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007–2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in-kind contributions (www.imi.europa.eu). KFC and IMA are funded by UK Research and Innovation (UKRI). KFC is an Emeritus Senior Investigator of the UK National Institute for Health Research (NIHR). We acknowledge the contribution of the whole U-BIOPRED team as listed below.U-BIOPRED Supplementary authorsNameAffiliationAbdel-Aziz MIDepartment of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsAdcock I MNational Heart and Lung Institute, Imperial College, London, UKAndersson LIDepartment of Respiratory Medicine, Karolinska University Hospital, Stockholm, SwedenAuffray CEuropean Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, FranceBadi YENational Heart and Lung Institute, Imperial College, London, UKBakke PDepartment of Clinical Science, University of Bergen, Bergen, NorwayBansal ATAcclarogen Ltd, St. John's Innovation Centre, Cambridge, UKBaribaud FJanssen R&D, LLC, Spring House, PA, USABates SRespiratory Therapeutic Unit, GSK, London, UKBel EHAcademic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsBigler JPreviously Amgen IncBilling BDepartment of Respiratory Medicine, Karolinska University Hospital, Stockholm, SwedenBisgaard HCOPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital,University of Copenhagen, Copenhagen, DenmarkBoedigheimer MJAmgen Inc.; Thousand Oaks, USABønnelykke KCOPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, DenmarkBrandsma JUniversity of Southampton, Southampton, UKBrinkman PAcademic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsBucchioni EChiesi Pharmaceuticals SPA, Parma, ItalyBurg DCentre for Proteomic Research, Institute for Life Sciences, University of Southampton, Southampton, UKBush ANational Heart and Lung Institute, Imperial College, London, UK; Royal Brompton and Harefield NHS trust, UKCaruso MDept. Clinical and Experimental Medicine, University of Catania, Catania, ItalyChalekis RInstitute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenChanez PAssistance publique des Hôpitaux de Marseille - Clinique des bronches, allergies et sommeil, Aix Marseille Université, Marseille, FranceChung FKNational Heart and Lung Institute, Imperial College, London, UKCheca TInstitute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenCompton CHRespiratory Therapeutic Unit, GSK, London, UKCorfield JAreteva R&D, Nottingham, UKCunoosamy DSanofi, Cambridge, USAD'Amico AUniversity of Rome ‘Tor Vergata’, Rome ItalyDahlén BDepartment of Respiratory Medicine, Karolinska University Hospital & Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenDahlén SEInstitute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, and Department of Respiratory Medicine, Karolinska University Hospital, Stockholm, SwedenDe Meulder BEuropean Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, FranceDjukanovic RNIHR Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, Southampton, UKErpenbeck VJTranslational Medicine, Respiratory Profiling, Novartis Institutes for Biomedical Research, Basel, SwitzerlandErzen DBoehringer Ingelheim Pharma GmbH & Co. KG; Biberach, GermanyFichtner KBoehringer Ingelheim Pharma GmbH & Co. KG; Biberach, GermanyFleming LJNational Heart and Lung Institute, Imperial College, London, UK; Royal Brompton and Harefield NHS trust, UKFormaggio EPreviously CROMSOURCE, Verona ItalyFowler SJDivision of infection, immunity and respiratory medicine, School of biological sciences, University of Manchester, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United KingdomFrey UUniversity Children's Hospital, Basel, SwitzerlandGahlemann MBoehringer Ingelheim (Schweiz) GmbH, Basel, SwitzerlandGeiser TDepartment of Respiratory Medicine, University Hospital Bern, SwitzerlandGoss VNIHR Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, UKGuo YData Science Institute, Imperial College, London, UKHashimoto SAcademic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsHaughney JInternational Primary Care Respiratory Group, Aberdeen, ScotlandHedlin GDept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenHekking PWAcademic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsHigenbottam TAllergy Therapeutics, West Sussex, UKHohlfeld JMFraunhofer Institute for Toxicology and Experimental Medicine, Hannover, GermanyHolweg CRespiratory and Allergy Diseases, Genentech, San Francisco, USAHorváth ISemmelweis University, Budapest, HungaryHowarth PNIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UKJames AJInstitute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenKnowles RGKnowles Consulting Ltd, Stevenage. UKKolmert JInstitute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenKonradsen JDept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenKrug NFraunhofer Institute for Toxicology and Experimental Medicine, Hannover, GermanyLazarinis NDepartment of Respiratory Medicine, Karolinska University Hospital & Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenLi C-XDepartment of Medicine Solna, Karolinska Institutet, Stockholm, SwedenLoza MJJanssen R&D, LLC, Spring House, PA, USALutter RAcademic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsManta ARoche Diagnostics GmbH, Mannheim, GermanyMasefield SEuropean Lung Foundation, Sheffield, UKMaitland-van der Zee Anke-HilseDepartment of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsMatthews JGRespiratory and Allergy Diseases, Genentech, San Francisco, USAMazein AEuropean Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, FranceMiddelveld RJMCentre for Allergy Research, Karolinska Institutet, Stockholm, SwedenMiralpeix MAlmirall, Barcelona, SpainMontuschi PUniversità Cattolica del Sacro Cuore, Milan, ItalyMurray CSDivision of infection, immunity and respiratory medicine, School of biological sciences, University of Manchester, Manchester University NHS Foundation Trust, and Manchester Academic Health Science Centre, Manchester, United KingdomMusial JDept. of Medicine, Jagiellonian University Medical College, Krakow, PolandMumby, SNational Heart and Lung Institute, Imperial College, London, UKMyles DRespiratory Therapeutic Unit, GSK, London, UKNordlund BDept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenPandis IData Science Institute, Imperial College, London, UKPavlidis SNational Heart and Lung Institute, Imperial College, London, UKPostle AUniversity of Southampton, UKPowel PEuropean Lung Foundation, Sheffield, UKPraticò GCROMSOURCE, Verona, ItalyPuig Valls MCROMSOURCE, Barcelona, SpainRao NJanssen R&D, LLC, Spring House, PA, USAReinke SInstitute of Environmental Medicine, Karolinska Institutet, Stockoholm, SwedenRiley JRespiratory Therapeutic Unit, GSK, London, UKRoberts AAsthma UK, London, UKRoberts GNIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UKRowe AJanssen R&D, UKSandström TDept of Public Health and Clinical Medicine, Umeå University, Umeå, SwedenSchofield JPRCentre for Proteomic Research, Institute for Life Sciences, University of Southampton, Southampton, UKSeibold WBoehringer Ingelheim Pharma GmbH, Biberach, GermanyShaw DERespiratory Research Unit, University of Nottingham, UKSigmund RBoehringer Ingelheim Pharma GmbH & Co. KG; Biberach, GermanySinger FPediatric Respiratory Medicine, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandSkipp PJCentre for Proteomic Research, Institute for Life Sciences, University of Southampton, Southampton, UKSmicker MSanofi, Cambridge, USASousa ARRespiratory Therapeutic Unit, GSK, London, UKSparreman-Mikus MDepartment of Medicine Huddinge, Karolinska Institutet, and Department of Respiratory Medicine, Karolinska University Hospital, Stockholm, SwedenSterk PJAcademic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsStröm MDepartment of Medicine Solna, Karolinska Institutet, Stockholm, SwedenSun KData Science Institute, Imperial College, London, UKThornton BMSD, USAUddin MAstraZeneca BioPharmaceuticals R&D, Gothenburg, SwedenVersi ANational Heart and Lung Institute, Imperial College, London, UKVestbo JCentre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester Academic Health Sciences Centre, Manchester, United KingdomVissing NHCOPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, DenmarkWagers SSBioSci Consulting, Maasmechelen, BelgiumWheelock ARespiratory Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; and Department of Respiratory Medicine and Allergy, Karolinska University Hospital Solna, Stockholm, SwedenWheelock CEInstitute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, Stockholm, SwedenWilson SJHistochemistry Research Unit, Faculty of Medicine, University of Southampton, Southampton, UKYasinska VDepartment of Medicine Huddinge, Karolinska Institutet, and Department of Respiratory Medicine, Karolinska University Hospital, Stockholm, SwedenZounemat Kermani, NData Science Institute, Imperial College, London, UK COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark Funding Information: U‐BIOPRED has received funding from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007–2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in‐kind contributions ( www.imi.europa.eu ). KFC and IMA are funded by UK Research and Innovation (UKRI). KFC is an Emeritus Senior Investigator of the UK National Institute for Health Research (NIHR). We acknowledge the contribution of the whole U‐BIOPRED team as listed below. Publisher Copyright: © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2023/11
Y1 - 2023/11
N2 - Background: Because of altered airway microbiome in asthma, we analysed the bacterial species in sputum of patients with severe asthma. Methods: Whole genome sequencing was performed on induced sputum from non-smoking (SAn) and current or ex-smoker (SAs/ex) severe asthma patients, mild/moderate asthma (MMA) and healthy controls (HC). Data were analysed by asthma severity, inflammatory status and transcriptome-associated clusters (TACs). Results: α-diversity at the species level was lower in SAn and SAs/ex, with an increase in Haemophilus influenzae and Moraxella catarrhalis, and Haemophilus influenzae and Tropheryma whipplei, respectively, compared to HC. In neutrophilic asthma, there was greater abundance of Haemophilus influenzae and Moraxella catarrhalis and in eosinophilic asthma, Tropheryma whipplei was increased. There was a reduction in α-diversity in TAC1 and TAC2 that expressed high levels of Haemophilus influenzae and Tropheryma whipplei, and Haemophilus influenzae and Moraxella catarrhalis, respectively, compared to HC. Sputum neutrophils correlated positively with Moraxella catarrhalis and negatively with Prevotella, Neisseria and Veillonella species and Haemophilus parainfluenzae. Sputum eosinophils correlated positively with Tropheryma whipplei which correlated with pack-years of smoking. α- and β-diversities were stable at one year. Conclusions: Haemophilus influenzae and Moraxella catarrhalis were more abundant in severe neutrophilic asthma and TAC2 linked to inflammasome and neutrophil activation, while Haemophilus influenzae and Tropheryma whipplei were highest in SAs/ex and in TAC1 associated with highest expression of IL-13 type 2 and ILC2 signatures with the abundance of Tropheryma whipplei correlating positively with sputum eosinophils. Whether these bacterial species drive the inflammatory response in asthma needs evaluation.
AB - Background: Because of altered airway microbiome in asthma, we analysed the bacterial species in sputum of patients with severe asthma. Methods: Whole genome sequencing was performed on induced sputum from non-smoking (SAn) and current or ex-smoker (SAs/ex) severe asthma patients, mild/moderate asthma (MMA) and healthy controls (HC). Data were analysed by asthma severity, inflammatory status and transcriptome-associated clusters (TACs). Results: α-diversity at the species level was lower in SAn and SAs/ex, with an increase in Haemophilus influenzae and Moraxella catarrhalis, and Haemophilus influenzae and Tropheryma whipplei, respectively, compared to HC. In neutrophilic asthma, there was greater abundance of Haemophilus influenzae and Moraxella catarrhalis and in eosinophilic asthma, Tropheryma whipplei was increased. There was a reduction in α-diversity in TAC1 and TAC2 that expressed high levels of Haemophilus influenzae and Tropheryma whipplei, and Haemophilus influenzae and Moraxella catarrhalis, respectively, compared to HC. Sputum neutrophils correlated positively with Moraxella catarrhalis and negatively with Prevotella, Neisseria and Veillonella species and Haemophilus parainfluenzae. Sputum eosinophils correlated positively with Tropheryma whipplei which correlated with pack-years of smoking. α- and β-diversities were stable at one year. Conclusions: Haemophilus influenzae and Moraxella catarrhalis were more abundant in severe neutrophilic asthma and TAC2 linked to inflammasome and neutrophil activation, while Haemophilus influenzae and Tropheryma whipplei were highest in SAs/ex and in TAC1 associated with highest expression of IL-13 type 2 and ILC2 signatures with the abundance of Tropheryma whipplei correlating positively with sputum eosinophils. Whether these bacterial species drive the inflammatory response in asthma needs evaluation.
KW - Haemophilus influenzae
KW - Moraxella catarrhalis
KW - Tropheryma whipplei
KW - severe asthma
KW - α-diversity
UR - http://www.scopus.com/inward/record.url?scp=85163082775&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/all.15776
DO - https://doi.org/10.1111/all.15776
M3 - Article
C2 - 37287344
SN - 0105-4538
VL - 78
SP - 2906
EP - 2920
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 11
ER -